REG - Indivior PLC - Appointment of Independent Non-Executive Director

IndiviorAnnouncement

21/03/2024 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU8357Ha&default-theme=true

RNS Number : 8357H  Indivior PLC  21 March 2024

Indivior PLC

Appointment of Independent Non-Executive Director

 

Slough, UK, and Richmond, VA, March 21, 2024 - The Board of Indivior PLC
(LSE/Nasdaq: INDV) today announces the appointment of David E. Wheadon, M.D.
as an Independent Non-Executive Director of the Company with effect from June
1, 2024.  Dr. Wheadon is a health policy leader and physician with more than
three decades of global experience in the pharmaceutical industry.

 

Graham Hetherington, Chair, commented:

'We are delighted to announce David's appointment as an Independent
Non-Executive Director. David has extensive experience in the
biopharmaceutical industry and expertise in global heath policy and regulatory
affairs, product quality and patient safety. He will be a tremendous asset as
we continue to focus on our purpose of pioneering life-transforming treatments
for substance use disorders, serious mental illness and accidental overdose.'

 

Dr. Wheadon previously served as senior vice president of global regulatory
affairs, patient safety, and quality assurance at AstraZeneca Plc from
December 2014 to July 2019. Prior to that, he was executive vice president,
research and advocacy at Juvenile Diabetes Research Foundation International
Inc., from May 2013 to December 2014, and senior vice president, scientific
and regulatory affairs at Pharmaceutical Research and Manufacturers of America
(PhRMA), from January 2009 to May 2013. Dr. Wheadon served as vice president,
global pharmaceutical regulatory and medical science, and group vice
president, global pharmaceutical regulatory affairs at Abbott Laboratories
from 2005 to 2009. Prior to Abbott Laboratories, Dr. Wheadon held senior
regulatory and clinical development leadership positions at GlaxoSmithKline
Plc and Eli Lilly and Company.

 

Dr. Wheadon received his M.D. from Johns Hopkins University School of Medicine
and an A.B. in Biology from Harvard University.  He completed his
postdoctoral training in Psychiatry at Tufts/New England Medical Center in
Boston, Massachusetts.

 

Dr. Wheadon is a Non-executive Independent Director of Sotera Health Company
(Nasdaq: SHC), Vaxart, Inc (Nasdaq: VXRT), and ConnectiveRx. He also serves as
a member of the Board of Trustees of Mount Sinai Health System. Prior to its
recent acquisition by Bristol-Myers Squibb Company, Dr. Wheadon served as a
Non-executive Independent Director of Karuna Therapeutics, Inc (NASDAQ: KRTX).

 

There is no further information to disclose in relation to Dr. Wheadon's
appointment in accordance with LR 9.6.13.

 

About Indivior

 

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat addiction and serious mental illnesses.
Our vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of substance use disorder (SUD). Indivior is dedicated to transforming SUD
from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,100
individuals globally and its portfolio of products is available in 37
countries worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts:

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUAOORSUUOUAR